The CAB members are senior, highly experienced individuals, who understand the needs of the industry. They offer advice and assistance in the construction and evolution of all aspects of the BSc curriculum and represent a breadth of disciplines, companies and experience. It is my pleasure to introduce you to the University of Lincoln’s BSc in Pharmaceutical Science CAB. Over time, new members will join the CAB and as they do, they will appear here.
If you are thinking of embarking upon an exciting and highly worthwhile career in pharmaceutical science, then this could be the degree for you.
Global Head and Vice President of Clinical Pharmacology at Eisai Ltd
David received his degree in Pharmacology from Liverpool University. He then did a PhD in drug metabolism at Bradford University investigating the enzyme aldehyde oxidase. Since 1990 David has worked in the pharmaceutical industry, including spells at Wyeth, Roche and Celltech. He has had significant experience of in vivo preclinical pharmacology, drug metabolism and pharmacokinetics. Since 2001 David has worked as a Clinical Pharmacologist at Eisai. His current position is Global Head and Vice President of Clinical Pharmacology. David is a member of various organizations including the British Pharmacological Society (1994), the American Society for Clinical Pharmacology and Therapeutics (2002), the Steering Committee of the Industry Pharmacogenomics Working Group (2003), the Association of the British Pharmaceutical Industry Stratified Medicine Working Group (2010), the International Consortium for Innovation and Quality in Pharmaceutical Development; Clinical Pharmacology Leadership Group (2011) and the Pharma Integra Ltd Scientific Advisory Board (2008).
Head of Analytical and ADME* at Redxpharma Ltd
Stuart has over 20 year’s experience spanning both regulated bioanalytical investigations and drug discovery adsorption, distribution, metabolism and excretion (*ADME) screening for multi-national pharmaceutical companies and Contract Research Organizations. His career is distinguished by progressive applications of newer analytical technologies to characterize an expanding and ever more complex chemical space, specifically in the support ADME.
Immediately prior to RedxOncology, Stuart was VP of Analytical Operations Xceleron, a Company specializing in the application of accelerator mass spectrometry to shorten the drug development trajectory. Prior to this, Stuart was with Merck in Scotland where he spent seven years with Organon then Schering-Plough. He acted as bioanalytical site lead and supported critical ADME and pharmacology investigations, including analysis of endogenous compounds. Stuart’s team employed a range of sample preparation and detectors, including parallel columns systems, UPLC, linear ion trap and QToF systems. Stuart also spent time with Charles River (Inveresk Research) and Bioanalytical Analytical Systems. Most of his analytical time during this period was with LC-MS/MS, GC-MS systems.
Stuart completed his PhD at the School of Pharmaceutical Sciences, University of Strathclyde. He has a degree in Pharmacy from the University of Strathclyde and is on the register of the Pharmaceutical Society of Great Britain.
Head, Nonclinical Regulatory Strategy at Covance
Visiting Professor of Toxicology, University of Lincoln
Paul has a BSc (1983) in Zoology and PhD (1988) in membrane physiology from Durham University and joined Covance in 1998. He has nearly 25 years in compound development (CRO, UK and Belgium industry; latterly as Head of Toxicology) and has wide experience in all aspects of nonclinical support for the development of many drug classes, with expertise in regulatory issues and submissions; he has written approximately 50 peer-reviewed publications and book reviews and is a regular podium speaker and chairperson as well as a lecturer on training courses for a range of nonclinical topics.
Paul is a Registered Toxicologist and a Fellow of The British Toxicology Society (FBTS) as well as a member of the Society of Biology (formerly The Institute of Biology), Toxicokinetic Discussion Group (TKDG) and The Organisation for Professionals in Regulatory Affairs (TOPRA). He is also on the editorial board of Journal of Toxicology, Food and Chemical Toxicology and Regulatory Toxicology and Pharmacology. He is on the Executive Committee of the British Toxicology Society and a member of the Association of the British Pharmaceutical Industry (ABPI) Nonclinical Sciences and Biological Discovery Expert Network (NaBDEN) as well as various NC3Rs Working Groups.
Science Leader Bioavailability & ADME group, Nutrition Department, Unilever Research and Development
Dr Guus Duchateau is the lead scientist in the area of Bioavailability & ADME* and located within Unilever Research & Development, Vlaardingen, the Netherlands. Unilever Research and Development Vlaardingen is the main research facility for Unilever’s Foods Business. The Bioavailability & ADME group work with a range of in-silico, in-vitro and in-vivo models to study formulation aspects and the Absorption, Distribution, Metabolism and Excretion (*ADME) profile of nutrients, micronutrients and new functional food actives. Recently, we started to explore skin-formulation related ADME aspects.
Dr Duchateau was trained as a pharmacist at theUniversity of Amsterdam and completed his PhD in 1986 on bioavailability at Leiden University (the Netherlands). He started his career with a strong interest in instrumental analysis as applied to drug components, bio-fluids and pharmacokinetics, working in a Contract Research Organisation. His expertise was applied to phase I, II or III drug trials. Later, when he joined Unilever (1991) he moved to the area of nutrition related analysis and worked on edible oils and fats analysis, fat-replacers, fatty acid isomer analysis, as well as bio-fluid analysis.
Since 1999, he returned to the Bioavailability & ADME area, with a particular interest in the predictive value of physico-chemical and pharmacokinetic parameters, which determine bioavailability, but now applied to functional food ingredients. A range of typical, originally pharmaceutical, bioavailability models are now used in the area of nutrients and food active components such as phytosterols, minerals, polyphenols, sterol-glycosides and many other components.
Dr Duchateau has (co)-authored more then 50 papers in peer reviewed journals, a number of official methods, several book-chapters on analytical and bioavailability topics and has several patents.
Senior Research Scientist at AstraZeneca plc
Allan has a BSc (Tech) (1987) in Chemistry from University of Cardiff and a PhD (1992) in synthetic organic chemistry from University of Manchester. After post-doctoral positions at the University of Geneva where he investigated new approaches to anti-malarials, and at University of Nottingham studying sulfone chemistry, he joined Zeneca Pharmaceuticals in 1996 as a chemist in the Infection group.
For the last 15 years years Allan has been a senior research scientist in the Oncology group at AstraZeneca where he has been responsible for the synthesis of compounds from Lead Identification through to early development. He has significant experience in leading the synthetic chemistry effort in many Oncology drug discovery projects, specialising in the design and implementation of solutions to intractable synthetic routes to drug molecules up to candidate drug nomination.
Allan currently leads the AstraZeneca synthetic organic chemistry sandwich student program which annually aims to identify and recruit the best UK students into the AZ Oncology discovery group.
Pharmaceutical Consultant and Partner, Alacrity Pharma Associates
Keith graduated in Pharmacy (Leicester) and then completed a PhD in pharmaceutics (Bath). His career in the pharmaceutical industry began at Boots Pharmaceuticals where he undertook preformulation studies and formulation research support to development compounds and marketed products. Keith then moved to Fisons to lead tablet development projects with accountability for formulation and manufacture of clinical supplies. This included technology transfer into an Operations facility.
Following the acquisition of Fisons by Astra he continued to lead formulation development programmes for a range of products types across multiple therapy areas. Following the merger of Astra and Zeneca, Keith moved into a Project Management role and led cross-functional teams delivering the pharmaceutical development contribution for over 50 projects. One of these was the AZ compound ticagrelor (Brilinta/Brilique) where Keith has been Project Manager since the first study in man, through large complex clinical studies and finally to regulatory submission and approval in over 100 territories. As a consequence, he has extensive hands-on experience in all aspects of the end-to-end development process including addressing and resolving multiple issues associated with scale-up and technology transfer, clinical trial supplies (including comparators), working with CROs and life-cycle management. As the Brilinta submission was a full Quality by Design (QbD) dossier, Keith led the team through many Regulatory Authority meetings (FDA, EMEA, Health Canada) to establish the acceptance of Design Space principles.
Keith’s 30 year career within R&D based multinational pharmaceutical industry has given him an insight to the multiple challenges of drug discovery and development and how the industry has had to change and adapt. Since leaving AstraZeneca Keith is providing consultancy in pharmaceutical development as a Partner in Alacrity Pharma Associates and is also actively involved in pharmaceutical science education and mentoring.
Trained as a biochemist at University College Cardiff, Mark obtained his PhD in comparative drug metabolism (in vitro/in vivo correlation) from the University of London in 1988. He subsequently spent 12 years in the R&D Department at the Horseracing Forensic Laboratory, conducting in vivo metabolism studies on compounds potentially used for doping racehorses, and developing analytical methods (GC‑ and LC‑MS) to detect their use.
In 1999, he joined the Drug Metabolism Department at Covance, Harrogate, as a senior scientist, where he was involved in running and interpreting regulatory pre-clinical and clinical A(D)ME studies, principally for clients in the pharmaceutical industry.
In 2007, he moved to Xceleron, where he is currently Director of Science and Technology. The company specialises in biomedical applications of accelerator mass spectrometry (AMS), including human Phase 0 microdosing and enhanced Phase I studies using 14C microtracers, as a means of providing human pharmacokinetic and metabolism data at the earliest possible juncture during drug development.
Throughout his career, Mark’s research interests have focussed on novel analytical methodologies for drugs and their metabolites, including immunoaffinity chromatography; direct coupling of gas and liquid chromatography; the use of 13C:12C ratios to detect abuse of endogenous steroids in equine sport; and, latterly, accelerator mass spectrometry as an ultra-sensitive, enabling technique in biomedical research.